FECHAR
Feed

Já é assinante?

Entrar
Índice

Bibliografia

Última revisão: 29/03/2011

Comentários de assinantes: 0

Reproduzido de:

CADERNOS DE ATENÇÃO BÁSICA Nº 15 – HIPERTENSÃO ARTERIAL SISTÊMICA [Link Livre para o Documento Original]

MINISTÉRIO DA SAÚDE

Secretaria de Atenção à Saúde

Departamento de Atenção Básica

Série Cadernos de Atenção Básica – Série A. Normas e Manuais Técnicos

BRASÍLIA / DF – 2006

 

REFERÊNCIAS BIBLIOGRÁFICAS CITADAS NO TEXTO

1.   Mansur AP, Favarato D, Sousa MFM et al. Tendência do risco de morte por doenças circulatórias no Brasil de 1979 a 1996. Arq Bras Cardiol, 2001; 76(6): 497–503.

2.   Freitas OC, Resende CF, Marques NJ et al. Prevalence of hypertension in the urban population of Catanduva, in the State of Sao Paulo, Brazil. Arq Bras Cardiol, 2001; 77(1): 9–21.

3.   Fuchs FD, Moreira LB, Moraes RS et al. Prevalência de hipertensão arterial sistêmica e fatores associados na região urbana de Porto Alegre: estudo de base populacional. Arq Bras Cardiol, 1995; 63: 473–9.

4.   Lolio CA. Prevalência de hipertensão arterial em Araraquara. Arq Bras Cardiol, 1990; 55: 167–73.

5.   Lessa I. Epidemiologia da hipertensão arterial sistêmica e da insuficiência cardíaca no Brasil. Rev Bras Hipertens, 2001; 8: 383–92.

6.   O’Brien E et al. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ, 2001; 322: 531–6.

7.   Verdecchia P, Schillaci G, Borgioni C et al. White coat hypertension and white coat effect: similarities and differences. Am J Hypertens, 1995; 8: 790–8.

8.   IV Diretriz para uso da monitorização ambulatorial da pressão arterial / II Diretriz para o uso da monitorização residencial da pressão arterial. Arq Bras Cardiol 2005; 85,(supl. II): 5-18.

9.   Pickering TG, Hall JE, Lawrence JÁ, Falkner BE, Graves J, Hill MN. Recommendation for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans. A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111:697-716.

10. Hemmelgarn B, Zarnke KB, Campbell NRC, Feldman RD, McKay DW, McAlister FA, et al. The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 – Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2004; 20(1): 31-40.

11. European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23: 697-701.

12. Bortoloto LA, Henry O, Hanon O et al. Validation of two devices for self-measurement of blood pressure by elderly patients according to the revised British Hypertension Society protocol: the Omron HEM-722C and HEM-735C. Blood Press Monit, 1999; 4: 21–5.

13. Thijs L, Staessen JÁ, Celis H et al. Reference values for self-recorded blood pressure. A meta-analysis of summary data. Arch Intern Med, 1998; 158: 481–8.

14. O’Brien E, Coats A, Owens P et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ, 2000; 320: 1128–34.

15. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. Pediatrics 2004; 114 (2): 555-76.

16. World Health Organization. International Society of Hypertension Guidelines for the Management of Hypertension 1999. J Hypertens, 1999; 17: 151–83.

17. Zarnke KB, Levine M, McAlister FA et al. The 2000 Canadian recommendations for the management of hypertension: part two – Diagnosis and assessment of people with high blood pressure. Can J Cardiol, 2001; 17(12): 1249–63.

18. World Health Organization – International Society of Hypertension Guidelines for the Management of Hypertension, J Hypertens, 1999; 17: 151–83.

19. Kris-Etherton P, Eckel RH, Howard BV, Jeor SS et al. Lyon Diet Heart Study. Benefits of a Mediterranean-Style, National Cholesterol Education Program/American Heart Association Step I Dietary Pattern on Cardiovascular Disease. Circulation, 2001; 103: 1823–5.

20. Deckelbaum RJ, Fisher EA, Winston M, Kumanyika S, Lauer RM, Pi-Sunyer FX et al. AHA Conference Proceedings. Summary of a Scientific Conference on Preventive Nutrition: Pediatric to Geriatrics. Circulation, 1999; 100: 450–6.

21. Krauss RM, Eckel RH; Howard BH et al. AHA Dietary Guidelines. Revision 2000: A Statement for Healthcare Professionals from the Nutrition Committee of the American Heart Association. Stroke, 2000; 31: 2751–66.

22. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA, 1996; 275: 1590–7.

23. Whelton PK, He J, Cutler JÁ, Brancati FL, Appel LJ, Follmann D, Klag MJ. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. J Am Med Assoc 1997; 277(20): 1624–32.

24. McAlister FA, Levine N, Zarnke KB et al. The 2000 Canadian recommendations for the management of hypertension: Part one – therapy. Can J Cardiol, 2001; 17(5): 543–59.

25. Appel LJ, Moore TJ, Obarzanek E et al. DASH Collaborative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med, 1997; 336: 1117–24.

26. Moore TJ, Vollmer WM, Appel LJ et al. Effect of dietary patterns on ambulatory blood pressure. Results from the Dietary Approaches to Stop Hypertension (DASH) Trial. Hypertension, 1999; 34: 472–77.

27. Appel LJ, Brands MW, Daniels SR, et al. Dietary Approaches to Prevent and Treat Hypertension. A Scientific Statement From the American Heart Association. Hypertension. 2006;47:296.

28. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol, 1990; 132(4): 612–28.

29. Psaty BM, Smith NL, Siscovick DS et al. Health outcomes associated with antihpertensive therapies used as firstline agents. A systematic review and meta-analysis. JAMA 1977; 277: 739–45.

30. Wright JM, Lee C-H, Chamber GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug. CMAJ, 1999; 161: 25–32.

31. SHEP-Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA, 1991; 265: 3255–64.

32. UK Prospective Diabete Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabete. UKPDS 39. BMJ, 1998; 317: 713–20.

33. Blood Pressure Lowering Trialist’s Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet, 2000; 356: 1955–64.

34. Hansson L, Lindholm, Niskanen L et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality on hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet, 1999; 353:611–6.

35. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med, 2000; 342: 145–53.

36. PROGRESS Collaborative Group. Randomized Trial of a perindopril-based-blood pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001; 35: 1033–41.

37. Hansson L, Lindholm LH, Ekborn T et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 1999; 34: 1129–33.

38. Dahlof B, Devereux R; Kjeldsen S, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 2002, 359:995–1003.

39. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabete in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet, 2002; 359: 1004–10.

40. Stassen JÁ, Fagard R, Thijs L. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic hypertension in Europe (SYST–EUR). Lancet, 1997; 350:757–64.

41. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to doubleblind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, 2000; 356: 366–72.

42. Hansson L Hedner T Lund-Johansen P et al. Randomized trial of effects of calcium antagonists compared with diuretics and alpha-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazen (NORDIL) study. Lancet, 2000; 356:359–65.

43. Sykowsky PA, D’Agostino RB, Belanger AJ, Kannel WB. Secular Trends in Long Term Sustained Hypertension, Long Term Treatment and Cardiovascular Morbidity. The Framingham Heart Study 1950 to 1990. Circulation, 1996; 93: 697–703.

44. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet, 1998; 351: 1755–62.

45. Brenner BM, Cooper ME, Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabete and nephropathy N Engl J Med, 2001; 345:861–9.

46. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Reserach Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. The Antihypertensive and Lipid- LoweringTreatment to prevent Heart Attack Trial (ALLHAT). JAMA, 2000; 283: 1967–75.

47. Pahor M, Psaty BM, Alderman MH et al. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analyses of randomized controlled trials. Lancet, 2000; 356: 1949–54.

48. Flatcher MD, Yussuf S, Kober L et al for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patients. Lancet, 2000; 355: 1575–81.

49. Garg R, Yussuf S. Colaborative Group on ACE-inhibitor Trials. Overview of randomized trials of angiotensinconverting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA, 1995; 273: 1450–6.

50. Syst-Eur Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet, 1997; 350: 757–64.

51. Cohn JN, Ziesche S, Smith R, Anad I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Effect of calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation, 1997; 96:856–63.

52. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. US Carvedilol Heart failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med, 1996; 334: 1349–55.

53. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H Waagstein F, Kjekshus J, Wikstrand J. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and wellbeing in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERITHF). JAMA, 2000; 283: 1295–302.

54. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality with severe heart failure. N Engl J Med, 1999; 341: 709–17.

55. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G, Porcellati C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation, 1998; 97(1): 48–54.

56. Vasan RS, Larson MG, Leip EP et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med, 2001; 345: 1291–7.

57. The trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention. Phase I. JAMA; 1992; 267: 1213–20.

58. III Diretrizes Brasileiras sobre Dislipidemias e Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol, 2001; 77(supl III): 1–48.

59. Lindholm LH, Carlberg B, Samuelsson O. Should _ blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–53.

60. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet, 2005;366:2026-33.

 

REFERÊNCIAS COMPLEMENTARES

1.   World Health Organization. Global strategy on diet, physical activity and health. Fifty-seventh World Health Assembly. WHA 57 170.

2.   Ministério da Saúde. Secretaria de Assistência à Saúde. Coordenação Geral da Política de Alimentação e Nutrição. Guia Alimentar para a População Brasileira, 2005. Disponível em <www.saude/alimentacaoenutricao/documentos>. Acesso em 3 de novembro de 2005.

3.   Ministério da Saúde. Análise da Estratégia Global para Alimentação Saudável, Atividade Física e Saúde. Brasília, abril de 2004. Disponível em <www.saude/alimentacaoenutricao/documentos>. Acesso em 13 de maio de 2005.

4.   IV Diretriz Brasileira de Hipertensão. Hipertensão 2002;5:123-63. Disponível em www.sbh.org.br/documentos/index.asp.

5.   Fuchs FD. Hipertensão arterial sistêmica. Em: Duncan BB, Schmidt MI, Giugliani E, eds. 3a. ed. Medicina Ambulatorial: condutas em atenção primária baseadas em evidências. Porto Alegre: Artmed, 2004: 641-56.

 

SOBRE OS DIREITOS AUTORAIS DO DOCUMENTO

Consta no documento:

“Todos os direitos reservados. É permitida a reprodução parcial ou total desta obra, desde que citada a fonte e que não seja para venda ou qualquer fim comercial. A responsabilidade pelos direitos autorais de textos e imagens desta obra é de responsabilidade da área técnica. A coleção institucional do Ministério da Saúde pode ser acessada na íntegra na Biblioteca Virtual em Saúde do Ministério da Saúde: http://www.saude.gov.br/bvs.”

O objetivo do site MedicinaNet e seus editores é divulgar este importante documento. Esta reprodução permanecerá aberta para não assinantes indefinidamente.

 

Conecte-se

Feed

Sobre o MedicinaNET

O MedicinaNET é o maior portal médico em português. Reúne recursos indispensáveis e conteúdos de ponta contextualizados à realidade brasileira, sendo a melhor ferramenta de consulta para tomada de decisões rápidas e eficazes.

Medicinanet Informações de Medicina S/A

Cnpj: 11.012.848/0001-57

info@medicinanet.com.br


MedicinaNET - Todos os direitos reservados.

Termos de Uso do Portal

×
×

Em função da pandemia do Coronavírus informamos que não estaremos prestando atendimento telefônico temporariamente. Permanecemos com suporte aos nossos inscritos através do e-mail info@medicinanet.com.br.